Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients

Journal of Investigative Medicine

Volumn 61, Issue 8, 2013, Pages 1152-1160

  Esterson, Yonah B ^a   Zhang, Kehao ^a   Koppaka, Sudha ^a   Kehlenbrink, Sylvia ^a   Kishore, Preeti ^a   Raghavan, Pooja ^a   Maginley, Sylvan Roger ^a   Carey, Michelle ^a   Hawkins, Meredith ^a,b  

^a Division of Endocrinology   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adipose tissue inflammation; Insulin resistance; Obesity; Pioglitazone; Type 2 diabetes

Indexed keywords

ANTIINFLAMMATORY AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN SENSITIZING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PIOGLITAZONE; PLACEBO; RNA; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; UNCOUPLING PROTEIN 1;

ADULT; ARTICLE; BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENDRITIC CELL; DIABETIC OBESITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MACROPHAGE; MALE; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS ADIPOSE TISSUE BIOPSY; SUBCUTANEOUS FAT; ANTIINFLAMMATORY ACTIVITY; CELL INFILTRATION; INFLAMMATION; INSULIN SENSITIVITY; NEUTROPHIL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84896799696     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0000000000000017     Document Type: Article

References (41)

1. Alessi MC, Bastelica D, Morange P, et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 2000;49:1374-1380.
2. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001;60:349-356.
3. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796-1808.
4. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43:1271-1278.
5. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 1999;48:1270-1274.
6. Kim JK, Fillmore JJ, Sunshine MJ, et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest. 2004;114:823-827.
7. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thrombosis Vasc Biol. 1998;18:1-6.
8. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60:329-339.
9. Abeywardena MY, Leifert WR, Warnes KE, et al. Cardiovascular biology of interleukin-6. Curr Pharm Des. 2009;15:1809-1821.
10. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005; 54(suppl 2):S114-S124.
11. Sacks HS, Fain JN, Cheema P, et al. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care. 2011;34:730-733.
12. Kaneki M, Shimizu N, Yamada D, et al. Nitrosative stress and pathogenesis of insulin resistance. Antioxid Redox Signal. 2007;9:319-329.
13. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745YE751.
14. Wu H, Ghosh S, Perrard XD, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation. 2007;115:1029-1038.
15. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77:289-312.
16. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol. 2004;20:455-480.
17. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
18. Klappacher GW, Glass CK. Roles of peroxisome proliferator-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages. Curr Opin Lipidol. 2002;13:305-312.
19. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99:2416-2422.
20. Chmelar J, Chung KJ, Chavakis T. The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance. Thromb Haemost. 2013;109:399-406.
21. Lumeng CN. Innate immune activation in obesity. Mol Aspects Med. 2013;34:12-29.
22. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1-16.
23. Koppaka S, Kehlenbrink S, Carey M, et al. Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans. Diabetes. 2013.
24. Tonelli J, Li W, Kishore P, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes. 2004;53:1621-1629.
25. PatelJ, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diab, Obes Metab. 1999;1:165-172.
26. Porter SA, Massaro JM, Hoffmann U, et al. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care. 2009;32:1068-1075.
27. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med. 2002;34:217-224.
28. Ohno H, Shinoda K, Spiegelman BM, et al. PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 2012;15:395-404.
29. Sears IB, MacGinnitie MA, Kovacs LG, et al. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. Mol Cell Biol. 1996;16:3410-3419.
30. Tai TA, Jennermann C, Brown KK, et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem. 1996;271:29909-29914.
31. Wilson-Fritch L, Nicoloro S, Chouinard M, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest. 2004;114:1281-1289.
32. Tam CS, Xie W, Johnson WD, et al. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care. 2012;35:1605-1610.
33. Watts FG. Clinical diabetes research: methods and techniques. In: Roden M, ed. Practical Diabetes International. West Sussex, UK, 2007 John Wiley & Sons, Ltd. John Wiley & Sons Ltd; ISBN: 978 0 470 01728 9. 2008;25:277.
34. Esterson YB, Kishore P, Koppaka S, et al. Fatty acid-induced production of plasminogen activator inhibitor-1 by adipose macrophages is greater in middle-aged versus younger adult participants. J Gerontol A Biol Sci Med Sci. 2012;67:1321-1328.
35. Mauriege P, Imbeault P, Langin D, et al. Regional and gender variations in adipose tissue lipolysis in response to weight loss. J Lipid Res. 1999;40:1559-1571.
36. Spiegel AM, Hawkins M. 'Personalized medicine' to identify genetic risks for type 2 diabetes and focus prevention: can it fulfill its promise? Health Aff (Project Hope). 2012;31:43-49.
37. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
38. Smorlesi A, Frontini A, Giordano A, et al. The adipose organ: white-brown adipocyte plasticity and metabolic inflammation. Obesity reviews: an official journal of the International Association for the Study of Obesity 2012;13 Suppl 2:83-96.
39. Ahmadian M, Suh JM, Hah N, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557-566.
40. Defronzo RA, Mehta RJ, Schnure JJ. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract (1995). 2013;41:132-147.
41. Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetesVUnited States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep. 2004;53:1066-1068.